ClinicalTrials.gg
RecruitingNCT06739122Updated Aug 7, 2026

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

A Phase 3 interventional study of Dulaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Recruiting at 51 sites in 3 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Planned enrollment
40th of 54
55 · median 159
Started
2025
with 3 others
Phase 3
22 of 54
1 open now
Registered
50th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 40th largest by planned enrollment, is one of 4 that started in 2025, is one of 22 in phase 3, and was the 50th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening.
  • Have a body weight ≥50 kilograms (kg) and (BMI) of >85th percentile

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes
  • Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or dulaglutide within 8 weeks prior to screening
  • After the Type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
  • Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness within the last 6 months
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Have prior chronic, recurrent, or idiopathic pancreatitis, or known gallbladder disease
  • Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 8 weeks prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Dulaglutide

    Participants will receive dulaglutide subcutaneously (SC)

    Drug: Dulaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

    A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Week 26

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Dulaglutide

    Time frame: Predose through Week 30

  2. PK: Maximum Observed Concentration (Cmax) of Dulaglutide

    Time frame: Predose through Week 30

  3. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 26

  4. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 26

  5. Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 26

  6. Change from Baseline in the EQ-5D-Y-5L

    Time frame: Baseline, Week 26

  7. Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-B)

    Time frame: Baseline, Week 26

07

Study locations

44 of 51 sites recruiting
  • University of Arizona
    Tucson, Arizona 85724, United States
    Recruiting
    • · Contact520-626-3197
    • Sunil Sinha · Principal investigator
  • Arkansas Childrens Hospital
    Little Rock, Arkansas 72202-3500, United States
    Recruiting
    • · Contact505-272-5551
    • Jon Oden · Principal investigator
  • Division of Endocrinology, Diabetes, and Metabolism
    Los Angeles, California 90027, United States
    Recruiting
    • Lily Chao · Principal investigator
  • UCLA Mattel Children's Hospital
    Los Angeles, California 90095, United States
    Recruiting
    • · Contact310-203-7631
    • Vibha Singhal · Principal investigator
  • University of California, San Francisco
    San Francisco, California 94158, United States
    Recruiting
    • · Contact415-514-6234
    • Shylaja Sirinivasan · Principal investigator
  • Children's Hospital of Colorado
    Denver, Colorado 80045, United States
    Not yet recruiting
    • · Contact20-777-3618
    • Melanie Cree · Principal investigator
  • Yale Diabetes Research
    New Haven, Connecticut 06511, United States
    Recruiting
    • · Contact203-737-7177
    • Michelle Van Name · Principal investigator
  • Emerson Clinical Research Institute
    Washington D.C., District of Columbia 20009, United States
    Recruiting
    • · Contact202-239-0777
    • Julia Pineda · Principal investigator
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • · Contact888-884-2327
    • Shideh Majidi · Principal investigator
  • Nemours Children's Health
    Jacksonville, Florida 32207, United States
    Recruiting
    • Camila Pereira-Eshraghi · Principal investigator
  • D&H National Research Centers, Inc
    Miami, Florida 33155, United States
    Recruiting
    • · Contact786-375-6210
    • Yanetsi Flores Landa · Principal investigator
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
    Recruiting
    • · Contact407-896-2901
    • Konda Reddy · Principal investigator
  • D&H Tamarac Research Center, LLC
    Tamarac, Florida 33321, United States
    Recruiting
    • · Contact786-375-6210
    • Helena Gaviria · Principal investigator
  • University of South Florida
    Tampa, Florida 33612, United States
    Recruiting
    • Henry Rodriguez · Principal investigator
  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics
    Atlanta, Georgia 30329, United States
    Recruiting
    • Daniel Hsia · Principal investigator
  • Centricity Research Columbus Endocrinology
    Columbus, Georgia 31904, United States
    Recruiting
    • Steven Leichter · Principal investigator
  • St. Luke's Children's Endocrinology and Diabetes
    Boise, Idaho 83712, United States
    Recruiting
    • · Contact208-381-7340
    • Daniel Flynn · Principal investigator
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • · Contact312-307-9385
    • Roxana Aguirre Castaneda · Principal investigator
  • Center for Diabetes and Metabolic Diseases Indiana University
    Indianapolis, Indiana 46202, United States
    Recruiting
    • · Contact317-278-9699
    • Tamara Hannon · Principal investigator
  • University of Iowa Stead Family Children's Hospitals
    Iowa City, Iowa 52242, United States
    Recruiting
    • · Contact319-335-0077
    • Michael Tansey · Principal investigator
  • Norton Children's Endocrinology
    Louisville, Kentucky 40202, United States
    Recruiting
    • · Contact502-588-3400
    • Sara Watson · Principal investigator
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
    Recruiting
    • · Contact443-287-9032
    • Risa Wolf · Principal investigator
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
    Recruiting
    • · Contact601-815-5000
    • Nazmin Dixit · Principal investigator
  • University of New Mexico Hospital
    Albuquerque, New Mexico 87106, United States
    Recruiting
    • · Contact505-272-3073
    • Michelle Hutchison · Principal investigator
  • WBMD Pediatrics
    Buffalo, New York 14203, United States
    Recruiting
    • Kathleen Bethin · Principal investigator
  • Cohen Children's Medical Center Division of Pediatric Endocrinology
    Hyde Park, New York 11042, United States
    Recruiting
    • · Contact516-472-3750
    • Benjamin Nwosu · Principal investigator
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
    Recruiting
    • · Contact315-464-9006
    • David Hansen · Principal investigator
  • UNC Children's Hospital
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • · Contact919-966-2333
    • Nina Jain · Principal investigator
  • Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • · Contact513-803-7274
    • Ryan Brady · Principal investigator
  • Cleveland Clinic Childrens Outpatient Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • · Contact216-636-2828
    • Roy Kim · Principal investigator
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
    • · Contact405-271-6764
    • Jeanie Tryggestad · Principal investigator
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Steven Willi · Principal investigator
  • St Christophers Hospital For Children
    Philadelphia, Pennsylvania 19134, United States
    Recruiting
    • · Contact215-427-7911
    • Elizabeth Suarez · Principal investigator
  • Prisma Health Pediatric Endocrinology
    Columbia, South Carolina 29203, United States
    Recruiting
    • · Contact803-434-7990
    • Alison Lunsford · Principal investigator
  • Prisma Health Midlands
    Greenville, South Carolina 29615, United States
    Recruiting
    • · Contact864-454-5656
    • Elaine Apperson · Principal investigator
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
    Recruiting
    • · Contact248-817-4331
    • Heidi Shea · Principal investigator
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Siripoom McKay · Principal investigator
  • UT Health Houston
    Houston, Texas 77030, United States
    Recruiting
    • · Contact713-500-7257
    • Anvi Shah · Principal investigator
  • University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
    • Jacqueline Chan · Principal investigator
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Recruiting
    • · Contact206-987-3897
    • Petter Bjornstand · Principal investigator
  • Children's Wisconsin - Milwaukee Campus
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • · Contact414-955-8486
    • Susanne Cabrera · Principal investigator
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, C1425, Argentina
    Recruiting
    • · Contact011 4804-6669
    • Evelyn Blanc · Principal investigator
  • Centro de Investigaciones Médicas Mar del Plata
    Mar del Plata, B7600FYK, Argentina
    Not yet recruiting
    • · Contact0223 4917628
    • Mariela Colantonio · Principal investigator
  • INECO Neurociencias Oroño
    Rosario, 2000, Argentina
    Recruiting
    • · Contact+54 9 3417 56-7348
    • María Cappiello · Principal investigator
  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L
    San Miguel de Tucumán, T4000IHE, Argentina
    Recruiting
    • · Contact+5493815455588
    • Ana Fernandez Alonso · Principal investigator
  • Go Centro Medico San Nicolás
    San Nicolás, 2900, Argentina
    Recruiting
    • · Contact+5493364281994
    • Paulina Lanchiotti · Principal investigator
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares
    Ciudad Madero, 89440, Mexico
    Not yet recruiting
    • · Contact833 126 0055
    • Rafael Violante Ortiz · Principal investigator
  • Hospital Angeles (HA) - Puebla
    Puebla City, 72190, Mexico
    Not yet recruiting
    • · Contact222 303 8350
    • Margarita Barrientos · Principal investigator
  • Clínica Cemain
    Tampico, 89210, Mexico
    Not yet recruiting
    • · Contact833 343 0717
    • Ricardo Salas Flores · Principal investigator
  • Innovacion y Desarrollo de Estrategias en Salud SA de CV
    Tlalpan, 14090, Mexico
    Not yet recruiting
    • Maria Fernanda Castilla Peon · Principal investigator
  • Arké SMO S.A de C.V
    Veracruz, 91910, Mexico
    Not yet recruiting
    • · Contact2299314102
    • Maria del Carmen Ramon Ramirez · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 35 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 18, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06739122
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Jan 10, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion